Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings

Glaukos Corp (NYSE:GKOS) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

Revenue came in at $211.03 million, topping the analyst estimate of $168.22 million by 25.4%. Non-GAAP earnings per share were $0.47, compared with an expected loss of 10 cents. That is a 570% surprise.

The company lifted 2026 net sales guidance to $775 million to $785 million, up from $680 million to $700 million.

“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Glaukos shares jumped 17.4% to $213.00 in pre-market trading

These analysts made changes to their price targets on Glaukos following earnings announcement.

• Needham analyst David Saxon maintained the stock with a Buy and raised the price target from $201 to $251.
• BTIG analyst Ryan Zimmerman maintained the stock with a Buy and boosted the price target from $205 to $234.
• Stifel analyst Tom Stephan maintained the stock with a Buy and raised the price target from $190 to $225.

Photo via Shutterstock